OncoMatch/Clinical Trials/NCT05865743
Perioperative SDD to Prevent Infectious Complications After Esophagectomy
Is NCT05865743 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies SDD for esophageal cancer.
Treatment: SDD — The primary aim of the PERSuaDER-trial is to evaluate the effect of SDD on infectious complications after esophagectomy, focussed on the prevention of pneumonia
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1B-4A, N0-3
cT1b-4a,N0-3,M0
Prior therapy
Cannot have received: upper gi surgery
Lab requirements
Kidney function
No chronic renal failure (GFR < 15 mls/min) or chronic intermittent hemo- or peritoneal dialysis
Patients with documented chronic renal failure (GFR < 15 mls/min) or who are on chronic intermittent hemo- or peritoneal dialysis [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify